Hormonal treatment remains the standard of care in early HR+/HER2− breast cancer either alone or combined with a CDK4/6-inhibitor for high-risk patients, while HER2- antibodies (trastuzumab with or without pertuzumab) combined with chemotherapy remain a cornerstone in the treatment of HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.